PYRIMIDINE COMPOUNDS AND USE THEREOF

摘要

The invention relates to novel pyrimidine compounds of general formula (I), in which: A represents a group C=W or CRR; B represents a chemical bond or a group CRR ; X represents O, S, a group N-R or a group CRR; D represents C=O or a chemical bond; E represents a linear or branched 2- to 10-membered alkylene chain that, as members of a chain, can have 1 or 2 non-adjacent heteroatom group(s) K, which is selected among O, S, S(O), S(O)2 and N-R

and which can comprise a carbonyl group and/or a cycloalkanediyl group and/or a double or triple bond; W represents oxygen or sulfur; Z, together with the carbon atoms, to which it is bound, represents a condensed, optionally substituted 5-, 6- or 7-membered carbocyclic compound or heterocyclic compound that has 1, 2, 3 or 4 heteroatoms, which are selected among N, O and S; J represents CH2, CH2-CH2 or CH2-CH2-CH2; M represents CH or N; Y represents CH2, CH2-CH2 or CH2-CH2-CH2 or M-X, together, represent CH=C or CH2-CH=C; n is 0 or 1, and; R, R, R, R, R, R, R, R, R , R, R

, R<1>, R<2>, R<3>, R<4>, R<5> and R<6> have the meanings cited in the claims and in the description. The invention also relates to the physiologically compatible acid addition salts of the aforementioned compounds, and to the use of these compounds of general formula (I) and of the physiologically compatible acid addition salts of compounds (I) for producing a pharmaceutical agent for treating diseases, which respond to the influence of dopamine D3 receptor antagonists or agonists.